More Videos
- Getting to the Heart of the Merck-Abbott Embargo Break
- Merck: Both Sides Now
- A Public Hearing That Isn't Public
- Fighting The Flu Vaccine Critics
- Merck’s Mega-Monday Morning
- What Not To Wear At Sanofi-Pasteur
- Merck: Live Long And Prosper
- Lights, Camera, Lipitor!
- Biopharma's Bustin' Out All Over
- Friday At The Fat Fight
SPECIAL REPORT
MOST SHARED
- Stocks Overvalued, Recession Will Return: Meredith Whitney
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- U.S. May Wind Up Green With Envy
- BofA Ex-Counsel: I Was 'Stunned' When I Got Fired
- Bernanke Offers Something For Everyone
- Fed Likely to Keep Rates Low Despite Dollar's Fall: Bernanke
- Solar Emerges From A Dark Period
- Oil Tomorrow
- Stanford Receiver to Release Funds Of Frozen Acounts
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Answers to Your Questions: A Path to Economic Disaster?
- 5 Ways to Play the Chinese Markets: Analyst
- Meredith Whitney: Turns Bearish
- 3 Stock Plays on Rising College Costs
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Nov. 16: Unusual Volume Leaders
- Getting to the Heart of the Merck-Abbott Embargo Break
- What MGM's Sale Could Say About Value of Content
- My Ratings on Lowe's & Home Depot: Analyst
- Buffett's Berkshire Hathaway Boosts Stake in Wal-Mart
- Time Warner to Spin Off AOL on December 9
- Gates Boosts Waste Management, Coca Cola Stakes
- What's Kept Stock Rally Going? Fear, Not Confidence
- Fed to Keep Rates Low Despite Dollar's Fall: Bernanke
- Citi Shares, A Strange Indicator Of Unemployment?
- Millions Could Have to Repay Part of Obama's Tax Credit
- Hollywood Turns to Porn as Unemployment Rises
- Slideshow: US Cities With Most Underwater Mortgages
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
Right on the heels of my previous blog entry about an analyst saying a Medicare reconsideration of its anemia drug reimbursement policy may be in the offing comes this news out of the agency.
It does not yet constitute a formal reconsideration by Medicare, but the agency today has sent a letter to U.S. Oncology, ASCO and ASH (American Society of Hematology) telling them that in order for Medicare to reconsider its anemia drug reimbursement level decision that the groups need to provide "new evidence" or "arguments" that the agency "misinterpreted existing evidence." Medicare is giving the groups 30 days to respond with a convincing case.
A Medicare spokesman says "courtesy copies" of the letter were also sent to about a dozen other interested parties possibly including Amgen [AMGN
Loading...
()
] and Johnson & Johnson [JNJ
Loading...
()
] and that another division may have sent federal lawmakers, who recently passed a bill urging reconsideration, copies of the letter as well.
Anemia drugs are multi-billion dollar products that are used to combat the sometimes overwhelming fatigue that occurs in cancer patients getting chemotherapy. The agency's under pressure to reloosen the purse strings when it comes to payment for the drugs. Recent reports and studies indicate doctors may have been overprescribing the drugs resulting in higher risk of heart trouble, tumor growth and death.
So, Medicare announced it was reducing its reimbursement levels. Cancer doctors balked. In the letter to the doctors' groups, Medicare says it did an "exhaustive review" of hundreds of studies and thousands of comment letters it had received to arrive at its new policy. Now, Medicare wants scientific proof that it should consider overriding its own decision.
Update: In a research note to clients FBR biotech analyst Jim Reddoch writes, "We do not expect CMS (Medicare) to change its stance. After this letter and our Washington consultants' interpretations of it, we think it is less likely CMS will change its coverage policy on Aranesp." Reddoch has a Market Perform rating and $56 price target on AMGN. FBR makes a market in Amgen.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes